ReviewCurrent opinion in urology2015
The epigenetics of prostate cancer diagnosis and prognosis: update on clinical applications.
Review in Current opinion in urology, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 27 citations in OpenAlex.
- Expression of hsv1-miR-H18 and hsv2-miR-H9 as a field defect marker for detecting prostate cancer.Prostate international · 2022Article
- A Study to Investigate the Role of Noncoding RNA miR146 Alpha as a Potential Biomarker in Prostate Cancer.Journal of analytical oncology · 2022Article
- MicroRNAs in treatment-induced neuroendocrine differentiation in prostate cancer.Cancer drug resistance (Alhambra, Calif.) · 2020Article
- A health disparities study of MicroRNA-146a expression in prostate cancer samples derived from African American and European American patients.Journal of solid tumors · 2020Article
- Aberrant SOCS3 Promoter Methylation as a Noninvasive Diagnostic Biomarker for Locally Advanced Prostate Cancer.Medeniyet medical journal · 2020Article
- DNA methylation in repeat negative prostate biopsies as a marker of missed prostate cancer.Clinical epigenetics · 2019Article
- Elevated expression of PTCD3 correlates with tumor progression and predicts poor prognosis in patients with prostate cancer.Molecular medicine reports · 2018Article
- Potential Epigenetic Biomarkers for Prostate Cancer Screening.International neurourology journal · 2018Article
- A panel of DNA methylation markers for the detection of prostate cancer from FV and DRE urine DNA.Clinical epigenetics · 2018Article
- Aberrant Promoter Methylation of Protocadherin8 (PCDH8) in Serum is a Potential Prognostic Marker for Low Gleason Score Prostate Cancer.Medical science monitor : international medical journal of experimental and clinical research · 2017Article
- Epigenomic Regulation of Androgen Receptor Signaling: Potential Role in Prostate Cancer Therapy.Cancers · 2017Review
- Heterogeneous patterns of DNA methylation-based field effects in histologically normal prostate tissue from cancer patients.Scientific reports · 2017Article
- LINE-1 methylation status in prostate cancer and non-neoplastic tissue adjacent to tumor in association with mortality.Epigenetics · 2017Article
- Methylation profiling identified novel differentially methylated markers including OPCML and FLRT2 in prostate cancer.Epigenetics · 2016Article
- Article
- Urine Cell-Free DNA Integrity Analysis for Early Detection of Prostate Cancer Patients.Disease markers · 2015Article
- DNA methylation as a dynamic regulator of development and disease processes: spotlight on the prostate.Epigenomics · 2015Review
- B lymphoma Moloney murine leukemia virus insertion region 1: An oncogenic mediator in prostate cancer.Asian journal of andrologyReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
Abstract
purpose of reviewThere is a major deficit in our ability to detect and predict the clinical behavior of prostate cancer (PCa). Epigenetic changes are associated with PCa development and progression. This review will focus on recent results in the clinical application of diagnostic and prognostic epigenetic markers. RECENT
findingsThe development of high throughput technology has seen an enormous increase in the discovery of new markers that encompass epigenetic changes including those in DNA methylation and histone modifications. Application of these findings to urine and other biofluids, but also cancer and noncancerous prostate tissue, has resulted in new biomarkers. There has been a recent commercial development of a DNA methylation-based assay for identifying PCa risk from normal biopsy tissue. Other biomarkers are currently in the validation phase and encompass combinations of multiple genes. SUMMARY: Epigenetic changes improve the specificity and sensitivity of PCa diagnosis and have the potential to help determine clinical prognosis. Additional studies will not only provide new and better biomarker candidates, but also have the potential to inform new therapeutic strategies given the reversibility of these processes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.